Co-Diagnostics
CODX
43 hedge funds and large institutions have $5.81M invested in Co-Diagnostics in 2024 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 3 closing their positions.
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
19% more capital invested
Capital invested by funds: $4.89M → $5.81M (+$916K)
13% more funds holding
Funds holding: 38 → 43 (+5)
0.03% more ownership
Funds ownership: 0.47% → 0.49% (+0.03%)
69% less call options, than puts
Call options by funds: $79K | Put options by funds: $252K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$130K |
| 2 |
KOC
Koss-Olinger Consulting
Gainesville,
Florida
|
+$71.4K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$64.6K |
| 4 |
TDC
Thompson Davis & Co
Richmond,
Virginia
|
+$50.3K |
| 5 |
VF
Virtu Financial
New York
|
+$33.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$51.9K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$26.5K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$23.2K |
| 4 |
Renaissance Technologies
New York
|
-$16.2K |
| 5 |
SAS
SMI Advisory Services
Columbus,
Indiana
|
-$12.3K |
CODX Hedge Fund Activity: Q2 2024 in Review
43 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Co-Diagnostics (CODX) for Q2 2024, worth a combined $5.81M — up 19% from $4.89M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CODX positions and 3 closed out — a net gain of 5 holders — while 12 added to existing stakes and 8 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $130K. The largest seller was D.E. Shaw & Co, exiting entirely with an estimated $51.9K sold.
- 43 institutional investors held Co-Diagnostics (CODX) as of Q2 2024, up from 38 in Q1 2024.
- Funds reported $5.81M of Co-Diagnostics stock for Q2 2024, up 19% quarter-over-quarter.
- 8 funds opened new Co-Diagnostics positions in Q2 2024 and 3 closed out, a net change of +5 holders.
- The largest Co-Diagnostics buyer in Q2 2024 was Susquehanna International Group, an estimated $130K added.
- The largest Co-Diagnostics seller in Q2 2024 was D.E. Shaw & Co, an estimated $51.9K sold.
Based on aggregated 13F filings for Q2 2024.